~176 spots leftby Apr 2026

Palliative Care for End Stage Liver Disease

(PAL-LIVER Trial)

Recruiting in Palo Alto (17 mi)
+17 other locations
MV
Overseen byManisha Verma, MBBS, MPH
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Albert Einstein Healthcare Network
Disqualifiers: MELD> 30, Life expectancy < 6 months
No Placebo Group
Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-Hep (Functional Assessment of Cancer Therapy- Hepatobiliary). 14 Clinical Centers across US are recruited to participate in this study.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Palliative Care for End Stage Liver Disease?

Research suggests that palliative care can improve quality of life and reduce symptoms for patients with advanced liver disease, similar to its benefits in cancer care. Although evidence is limited, early palliative care intervention has been shown to improve symptoms and encourage advance care planning for patients on liver transplant waiting lists.12345

Is palliative care safe for people with end-stage liver disease?

Palliative care is generally considered safe for people with end-stage liver disease, as it focuses on improving quality of life and reducing suffering. Studies suggest that it can help manage symptoms and improve end-of-life care planning without significant safety concerns.34678

How is palliative care different from other treatments for end-stage liver disease?

Palliative care for end-stage liver disease focuses on improving quality of life by managing symptoms and providing emotional and practical support, rather than trying to cure the disease. Unlike other treatments that may focus on the liver itself, palliative care addresses the overall well-being of the patient and their caregivers.248910

Research Team

MV

Manisha Verma, MBBS, MPH

Principal Investigator

Albert Einstein Healthcare Network

Eligibility Criteria

This trial is for patients with new or ongoing complications of End Stage Liver Disease, including liver cancer, regardless of their transplant status. They must have a caregiver willing to participate. It's not for those with a MELD score over 30 or an expected life expectancy under 6 months.

Inclusion Criteria

I have advanced liver disease or liver cancer and have a caregiver willing to participate.

Exclusion Criteria

Your liver disease is so severe (MELD score > 30) that you may not live more than 6 months.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive palliative care through either a consultative model or a trained hepatologist-led model, with in-person visits at initial, 1, 2, and 3 months

3 months
4 visits (in-person)

Follow-up

Participants are monitored for changes in quality of life, patient satisfaction, symptom burden, depression severity, and caregiver burden

3 months

Treatment Details

Interventions

  • Palliative Care (Behavioural Intervention)
Trial OverviewThe study compares two ways to provide palliative care: one where patients see a specialist and another where liver doctors are trained in palliative care. The main goal is to see how these approaches affect quality of life after three months using the FACT-Hep scale.
Participant Groups
2Treatment groups
Active Control
Group I: Model 1: Consultative Palliative CareActive Control1 Intervention
Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
Group II: Model 2: Trained Hepatologist- led PCActive Control1 Intervention
A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1

Palliative Care is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as Palliative Care for:
  • Symptom management for various conditions including cancer, neurological disorders, and end-of-life care

Find a Clinic Near You

Who Is Running the Clinical Trial?

Albert Einstein Healthcare Network

Lead Sponsor

Trials
65
Recruited
869,000+

Barry Freedman

Albert Einstein Healthcare Network

Chief Executive Officer since 2003

MBA with a focus on healthcare

Dr. Albert Villarin

Albert Einstein Healthcare Network

Chief Medical Officer since 2008

MD from Albert Einstein College of Medicine

Patient-Centered Outcomes Research Institute

Collaborator

Trials
592
Recruited
27,110,000+
Nakela L. Cook profile image

Nakela L. Cook

Patient-Centered Outcomes Research Institute

Chief Executive Officer since 2020

MD, MPH

Harv Feldman profile image

Harv Feldman

Patient-Centered Outcomes Research Institute

Chief Medical Officer

MD, MSCE

Findings from Research

Patients with advanced liver disease experience significant symptom burden and have considerable palliative care needs, highlighting the importance of improving their quality of life.
There is a global variability in the involvement of palliative care for these patients, indicating a need for further research and development of new care models to enhance access to specialist palliative services.
Emerging Role of Palliative Care in Patients with Advanced Liver Disease.Jordan, RI., Tandon, P.[2021]
Specialist palliative care can significantly improve symptoms and facilitate advance care planning for patients on liver transplant waiting lists, but these patients often receive limited palliative care support.
Healthcare professionals, particularly liver physicians, are hesitant to refer patients to palliative care due to concerns about the perceived curative nature of liver transplants and a lack of clarity on referral criteria.
Palliative Care for Patients with End-Stage Liver Disease on the Liver Transplant Waiting List: An International Systematic Review.Vijeratnam, SS., Candy, B., Craig, R., et al.[2022]
In a feasibility trial involving 36 patients with end-stage liver disease, long-term abdominal drains showed lower hospital resource utilization and costs compared to large-volume paracentesis, suggesting they may be a more efficient option for managing refractory ascites.
While complications like cellulitis and leakage were more common in the long-term drain group (41% vs. 11% in the paracentesis group), the overall safety profile and high questionnaire completion rates indicate that patients found long-term drains acceptable and potentially transformative for their care.
Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis.Macken, L., Bremner, S., Gage, H., et al.[2021]

References

Palliative care in liver disease: what does good look like? [2023]
Emerging Role of Palliative Care in Patients with Advanced Liver Disease. [2021]
Palliative Care for Patients with End-Stage Liver Disease on the Liver Transplant Waiting List: An International Systematic Review. [2022]
Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. [2021]
Outcomes of Palliative Care Consultations for Hospitalized Patients With Liver Disease. [2020]
Palliative Care and End-of-Life Outcomes in Patients Considered for Liver Transplantation: A Single-Center Experience in the US Midwest. [2023]
Do screening tools assess palliative care needs and 12-month mortality in patients admitted to hepatology in-patient wards? [2022]
Palliative care and end-stage liver disease: a critical review of current knowledge. [2020]
Palliative care in end-stage liver disease: Time to do better? [2019]
Palliative care in cirrhotic patients: Brief summary of recent AASLD guidance. [2022]